Xavier Fradera
0000-0002-6118-075X
Publication & Citation Trends
Most Cited Works
Publications
99 total
The Discovery of Bridged Benzoazepine Amides as Selective Allosteric Modulators of RIPK1.
Cited by 2
Semantic Scholar
Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors. OA
Cited by 4
Semantic Scholar
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing.
Cited by 13
Semantic Scholar
NMR Data‐Driven Docking of HDM2‐Inhibitor Complexes
Cited by 1
Semantic Scholar
Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors. OA
Cited by 5
Semantic Scholar
Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold.
Cited by 7
Semantic Scholar
Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators.
Cited by 6
Semantic Scholar
Research Topics
Advanced Chemical Physics Studies
(26)
Spectroscopy and Quantum Chemical Studies
(18)
Computational Drug Discovery Methods
(14)
Free Radicals and Antioxidants
(9)
Bone Metabolism and Diseases
(8)
Frequent Co-Authors
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States)
University of the Basque Country
University of Girona
NHS Lanarkshire
Barcelona Biomedical Research Park